Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisenstat, BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium; Sajeel Chowdhary

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisenstat, BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium, Sajeel Chowdhary

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	17
State	Published - Mar 2015

Disciplines

Medicine and Health Sciences

Cite this

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. / BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium, David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisenstat,; Chowdhary, Sajeel.
In: Neuro-oncology, Vol. 17, 03.2015.

Research output: Contribution to journal › Article › peer-review

BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium, David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisenstat, ; Chowdhary, Sajeel. / Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. In: Neuro-oncology. 2015 ; Vol. 17.

@article{9a53176ef9964277b7d405316a67ff70,

title = "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma",

author = "\{BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium\}, \{David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisenstat,\} and Sajeel Chowdhary",

note = "doi: 10.1093/neuonc/nou160.",

year = "2015",

month = mar,

language = "American English",

volume = "17",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

AU - BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium, David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, Agnieszka Cseh, Yali Fu, Julie Cong, Sven Wind, David D Eisens

AU - Chowdhary, Sajeel

N1 - doi: 10.1093/neuonc/nou160.

PY - 2015/3

Y1 - 2015/3

UR - https://pubmed.ncbi.nlm.nih.gov/25140039/

M3 - Article

VL - 17

JO - Neuro-oncology

JF - Neuro-oncology

ER -

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

Disciplines

Other files and links

Cite this